Focus Partners Wealth
ABUS icon

Focus Partners Wealth’s Arbutus Biopharma ABUS Stock Holding History

Focus Partners Wealth’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,821
Closed -$55.1K – 2202
2025
Q2 		$55.1K Sell
17,821
-191
-1% -$634 ﹤0.01% 1971
2025
Q1 		$62.9K Buy
18,012
+191
+1% +$637 ﹤0.01% 1831
2024
Q4 		$58.3K Hold
17,821
– – ﹤0.01% 1816
2024
Q3 		$68.6K Buy
+17,821
New +$68.4K ﹤0.01% 1533

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Focus Partners Wealth's ABUS Position: Q3 2025 in Review

Focus Partners Wealth sold out of Arbutus Biopharma (ABUS) in Q3 2025, closing a stake of 17,821 shares — an estimated $55.1K sold.

Focus Partners Wealth first reported a position in ABUS in Q3 2024 and held it in 4 quarters. The position peaked at $68.6K in Q3 2024. 166 funds tracked by Wall St. Rank hold ABUS as of Q3 2025.

  • Focus Partners Wealth reported no remaining Arbutus Biopharma position as of Q3 2025 after selling out during the quarter.
  • Focus Partners Wealth sold 17,821 Arbutus Biopharma shares in Q3 2025, an estimated $55.1K.
  • Focus Partners Wealth first reported a position in Arbutus Biopharma in Q3 2024 and held it in 4 quarters.
  • Focus Partners Wealth's Arbutus Biopharma position peaked at $68.6K in Q3 2024.
  • 166 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2025.

Based on Focus Partners Wealth's 13F filing for Q3 2025, filed 14 Nov 2025.